Trusted Resources: News & Meetings
Latest announcements and gatherings
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration With JCR Pharmaceuticals
Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd. announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II).
Hunter syndrome is caused by a deficiency of IDS and manifests in different forms. JR-141, applied with J-Brain Cargo®, JCR’s proprietary blood-brain barrier (BBB) technology, is engineered to transport the therapeutic enzyme across the BBB to directly reach the brain and address both the somatic and neuronopathic manifestations of the disease, which can lead to progressive cognitive decline.
BookmarkRelated Content
-
Enzyme Replacement Therapy With Galsulfase for Mucopolysaccharidosis Type VIMucopolysaccharidosis type VI (MPS VI) o...
-
Luna and Partners Work to Accelerate Therapies for Hunter SyndromeAdvocacy organizations—the National MP...
-
Drug Delivery for Neuronopathic Lysosomal Storage Diseases: Evolving Roles of the Blood Brain Barrier and Cerebrospi...Whereas significant strides have been ma...
-
A Guide to Understanding MPS IIMPS II is a mucopolysaccharide disease k...
-
Analysis of Cognitive Ability and Adaptive Behavior Assessment Tools Used in an Observational Study of Patients With...Mucopolysaccharidosis II (MPS II) is a r...
-
Treatment of Skeletal and Non-Skeletal Alterations of Mucopolysaccharidosis Type IVA by AAV-Mediated Gene TherapyMucopolysaccharidosis type IVA (MPSIVA) ...
-
Mucopolysaccharidoses (MPS) and Gene TherapyMucopolysaccharidoses (MPS) are a group ...
Powered by
